Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

185
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
185
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

236
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refractory epilepsy from lead poisoning.

BMJ neurology open·2026
Same author

Erratum to 2025 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Surgical management of acute myocardial infarction and associated complications: The Journal of Thoracic and Cardiovascular Surgery, Volume 170, Issue 5, 2025, Pages 1327-1344.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Fate of dilated ascending aorta after transcatheter aortic valve replacement.

JTCVS structural and endovascular·2026
Same author

Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.

ESC heart failure·2026
Same author

Structure-Guided Optimization of Novel Inhibitors of <i>Plasmodium</i> Lysyl-tRNA Synthetase with Multistage Activity against Malaria Parasites.

Journal of medicinal chemistry·2026
Same author

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

Nature cancer·2026

Related Experiment Video

Updated: Dec 18, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K

New Surgical Circulatory Support System Outcomes.

Danny Ramzy1, Edward Soltesz2, Mark Anderson3

  • 1From the Department of Cardiac Surgery, Cedars Sinai Medical Center, Los Angeles, California.

ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|June 17, 2020
PubMed
Summary

The new micro-axial surgical heart pump shows promising results in treating severe heart conditions like cardiogenic shock and cardiomyopathy. Early U.S. data indicates high survival rates and good native heart recovery after Impella 5.5 device support.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.8K
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
09:54

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

2.2K

Related Experiment Videos

Last Updated: Dec 18, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.0K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.8K
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
09:54

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

2.2K

Area of Science:

  • Cardiovascular Medicine
  • Medical Devices
  • Surgical Technology

Background:

  • The Impella 5.5 is a recently approved micro-axial surgical heart pump.
  • It is used for advanced heart failure and high-risk cardiac procedures.
  • Previous data on its U.S. clinical experience is limited.

Purpose of the Study:

  • To report the initial U.S. clinical experience with the Impella 5.5 heart pump.
  • To evaluate its safety and efficacy in various cardiac conditions.
  • To assess patient outcomes including survival and native heart function recovery.

Main Methods:

  • A retrospective analysis of data from 55 patients who received the Impella 5.5 implant across three U.S. centers.
  • Data collected included demographics, procedural details, hemodynamic parameters, and clinical outcomes.
  • Patients received the device for conditions including acute myocardial infarction with cardiogenic shock, postcardiotomy cardiogenic shock, and cardiomyopathy.

Main Results:

  • The primary indications for Impella 5.5 implantation were cardiomyopathy (45%) and acute myocardial infarction with cardiogenic shock (29%).
  • Overall survival to explant was 83.6%.
  • Of the patients successfully weaned off the device (63.6%), 76.1% recovered native heart function. No device-related strokes, hemolysis, or limb ischemia were reported.

Conclusions:

  • The micro-axial surgical heart pump (Impella 5.5) demonstrated successful clinical performance in providing hemodynamic support and ventricular unloading.
  • It is effective for patients with acute myocardial infarction with cardiogenic shock, decompensated cardiomyopathy, and those undergoing high-risk cardiac procedures.
  • This early U.S. experience suggests favorable survival and native heart recovery rates.